Detalles de la búsqueda
1.
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer.
PLoS One
; 18(1): e0280507, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36706086
2.
miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy.
Breast Cancer (Dove Med Press)
; 14: 25-39, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35256859
3.
Serglycin Is Involved in TGF-ß Induced Epithelial-Mesenchymal Transition and Is Highly Expressed by Immune Cells in Breast Cancer Tissue.
Front Oncol
; 12: 868868, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35494005
4.
MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro.
Sci Rep
; 11(1): 10893, 2021 05 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-34035375
Resultados
1 -
4
de 4
1
Próxima >
>>